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Abstract
Patients with myelofibrosis at intermediate‐1 risk according to the International Prognostic Score System are projected to a relatively long sur-
vival; nonetheless, they may carry significant splenomegaly and/or systemic constitutional symptoms that hamper quality of life and require
treatment. Since registrative COMFORT studies included only patients at intermediate‐2/high International Prognostic Score System risk, safety
and efficacy data in intermediate‐1 patients are limited. We report on 70 intermediate‐1 patients treated with ruxolitinib according to standard
clinical practice that were evaluated for response using the 2013 IWG‐MRT criteria. At 6 months, rates of spleen and symptoms response were
54.7% and 80% in 64 and 65 evaluable patients, respectively. At 3months, ruxolitinib‐induced grade 3 anemia and thrombocytopenia occurred inHematological Oncology. 2017;1–6. Copyright © 2017 John Wiley & Sons, Ltd.wileyonlinelibrary.com/journal/hon 1
2 PALANDRI ET AL.40.6% and 2.9% of evaluable patients, respectively. Notably, 11 (15.9%) patients experienced at least one infectious event ≥grade 2. Most
(82.6%) patients were still on therapy after a median follow‐up of 27 months. These data support the need for standardized guidelines that
may guide the decision to initiate ruxolitinib therapy in this risk category, balancing benefit expectations and potential adverse effects.
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Myelofibrosis (MF) is a progressive disease that is burdened by symp-
tomatic splenomegaly, debilitating systemic symptoms, worsening
cytopenias, and overall reduced survival.1 Prognosis is currently
assessed by the International Prognostic Scoring System (IPSS) at diag-
nosis,2 by the dynamic‐IPSS (DIPSS) over the follow‐up,3 and by the
DIPSS‐plus that includes also transfusion requirement, thrombocyto-
penia, and cytogenetic abnormalities.4 Molecular abnormalities includ-
ing driver (JAK2V617F/CALR/MPL) and subclonal (ASXL1/SRSF2)
mutations have been recently integrated in the mutation‐enhanced
IPSS (MIPSS) score.5 Balancing life expectancy (ranging between 6.5
and 14.2 y) and the risk of severe complications, intermediate‐1 IPSS
risk patients are not candidates for allogeneic hematopoietic stem cell
transplantation (alloSCT) in clinical routine, which is the only poten-
tially curative treatment option so far. Nonetheless, these patients
may carry severe splenomegaly and/or symptoms that are not taken
into consideration by commonly used prognostic scores but that ham-
per quality of life and may urge treatment.
Ruxolitinib is the first‐in‐class JAK1/JAK2 inhibitor currently
available for the treatment of MF‐related splenomegaly and/or symp-
toms.6,7 The registrative COMFORT studies randomized intermediate‐
2/high IPSS risk patients to receive either ruxolitinib or placebo
(COMFORT‐1)8 or best available therapy (COMFORT‐2).9 In this
setting, ruxolitinib proved clear superiority in spleen and symptoms
responses over control arms. The subsequent expanded access JUMP
trial enrolled also 163 patients at intermediate‐1 IPSS risk with a palpa-
ble spleen length ≥5 cm below left costal margin (LCM) that were
treated for a median time of 14.4 months. Results from this subanalysis
were consistent with findings for the total population, with similar
response and toxicity rates.10 However, only a few independent data
are available on this particular patients' population.11,12 Here, we evalu-
ated the outcome of 70 intermediate‐1 IPSS risk MF patients that were
treated with ruxolitinib in 16 Italian or German Hematology Centers.
Patients were homogeneously evaluated for responses according to
the 2013 International Working Group–Myeloproliferative Neoplasms
Research and Treatment (IWG‐MRT) criteria,13 with the aim to provide
independent and standardized data on safety and efficacy of ruxolitinib
therapy in this risk category.2 | METHODS
2.1 | Patients and treatment
Between August 2011 and January 2014, a total of 70 intermediate‐1
IPSS risk MF patients were treated with ruxolitinib in 15 Italian and 1German Hematology Centers. Patients received ruxolitinib after inclu-
sion in the JUMP trial (n = 51) or within a compassionate use program
(n = 19) and were evaluated for responses according to the 2013
IWG‐MRT criteria.13 The decision to start ruxolitinib treatment was
based on physician's discretion. Baseline clinical/laboratory features,
outcome measures (evolution into acute leukemia, death, and spleen/
symptoms responses), and toxicities were retrospectively recorded.
Primary myelofibrosis (PMF) and post‐Essential Thrombocythemia/
post‐Polycythemia Vera myelofibrosis (PET‐MF/PPV‐MF) were
diagnosed according to the WHO200814 or the IWG‐MRT criteria,15
respectively. Adverse events were evaluated according to the
Common Terminology Criteria for Adverse Events (CTCAE) v4.
Comorbidities were evaluated according to the Charlson Comorbidity
Index (CCI).16 Body mass index (BMI) was evaluated according to stan-
dard criteria; specifically, BMI ≥25 identified patients overweight.17 The
study was approved by the Institutional Review Board of each Institu-
tion and was conducted according to the Helsinki declaration.2.2 | Statistical analysis
Continuous variables were expressed as median and ranges and
categorical variables were presented as frequencies and percentages.
Regression logistic analysis was performed to correlate spleen/
symptoms responses with several baseline features, namely, sex,
primary/secondary MF, age >65 years, transfusion dependency, leuko-
cytosis (>25x109/L), presence of constitutional symptoms and blast
cells, palpable hepatomegaly, JAK2V617F mutation and mutation load,
severe (grade 3) marrow fibrosis, Charlson Comorbidity Index ≥2, over-
weight, large splenomegaly (spleen length palpable ≥10 and ≥15 cm
below LCM), Total Symptom Score (TSS) higher than the median value
(≥20) and severely increased (≥44). Survival analysis was calculated
from the date of ruxolitinib start to the time of death or last follow‐up,
whichever came first, and was performed by means of Kaplan‐Meier
curve. All tests were 2‐sided, and a P value less than .05 was considered
statistically significant. Analyses were performedwith IBM SPSS Statis-
tics 22 (IBM Analytics) and GraphPad Prism 6 (GraphPad Software).3 | RESULTS
3.1 | Study population
Between June 2011 and July 2016, 70 patients with intermediate‐1
risk MF were treated with ruxolitinib. Table 1 summarizes main
baseline clinical and laboratory data of the cohort at ruxolitinib start.
Twenty‐three (32.8%) patients were >65 year old, 6 (8.6%) had hemo-
globin <10 g/dL, 6 (8.6%) had leukocyte >25 × 109/L, and 30 (42.8%)
TABLE 1 Patients' characteristics at ruxolitinib start
Characteristics Patients (no. = 70)
Male sex, no. (%) 44 (62.8%)
Primary myelofibrosis, no. (%) 39 (55.7%)
Post‐essential Thrombocythemia MF, no. (%) 8 (11.4%)
Post‐polycythemia Vera MF, no. (%) 23 (32.9%)
JAK2V617F mutation, no. (% on 65 evaluable) 55 (84.6%)
Median age, years (range) 60 (26.5‐78.1)
Age > 65 years, no. (%) 23 (32.8%)
Median hemoglobin, g/dl (range) 12.7 (8.1‐16.7)
Hemoglobin <10 g/dl, no. (%) 6 (8.6%)
Transfusion dependent, no. (%) 2 (2.9%)
Median leukocyte, x109/l (range) 11.1 (2.7‐46.6)
WBC >25 x109/l, no. (%) 6 (8.6%)
Median platelet, x109/l (range) 290 (101‐1200)
PLT <200 x109/l, no. (%) 20 (28.6%)
Constitutional symptoms, no. (%) 31 (44.3%)
Palpable spleen, no. (%) 69 (98.6%)
Median cm below LCM (range) 10 (5‐30)
Spleen ≥10 cm below LCM, no. (%) 40 (57.1%)
Spleen ≥15 cm below LCM, no. (%) 26 (37.1%)
Palpable liver no. (%) 26 (37.1%)
Median Total symptom score (range) 20 (0‐90)
TSS >44, no. (%) 7 (10%)
Abnormal karyotype, no. (% on 32 evaluable) 8 (25.0%)
Unfavorable karyotype, no. (% on 32 evaluable) 2 (6.3%)
Grade 3 marrow fibrosis, no. (%) 15 (21.4%)
Median Charlson comorbidity index (range) 0 (0‐8)
CCI ≥2, no. (% on 59 evaluable) 19 (32.2%)
BMI > 25, no. (% on 59 evaluable) 30 (50.9%)
Median time MF‐RUX start, months (range) 19.2 (0.1‐203.3)
Time from MF‐RUX start >2 years, no. (%) 31 (44.3%)
RUX starting dose, no. (%)
10 mg BID 4 (5.7%)
15 mg BID 18 (25.7%)
20 mg BID 48 (68.6%)
Abbreviations: BMI, body mass index; CCI, Charlson Comorbidity Index;
LCM, left costal margin; MF, myelofibrosis; RUX, ruxolitinib; WBC, white
blood cells; PLT, platelets; BID, twice a day; TSS, Total Symptom Score.
FIGURE 1 Percentage of patients achieving a spleen response
PALANDRI ET AL. 3reported on constitutional symptoms; 5 (7.2%) patients had circulating
blasts in peripheral blood. Two patients were transfusion dependent
according to 2013‐IWG‐MRT criteria. A total of 40 (57.1%) patients
had a large splenomegaly (37.1% with spleen palpable ≥15 cm below
LCM). One patient did not present palpable splenomegaly at ruxolitinib
start and was therefore not evaluable for response; the remaining 69
patients had a baseline spleen length palpable of more than 5 cm
below left costal margin. Seven (10%) were heavily symptomatic, with
a baselineTotal Symptom Score (TSS) >44. Charlson Comorbidity Index
(CCI) was evaluated in 59 patients and was 0 in 27 (45.8%), one in 13
(22.0%), and ≥2 in 19 patients (32.2%). At 3 and 6 months, 69 and 65
patients were still on therapy, respectively.3.2 | Spleen and symptom responses
Per intention‐to‐treat analysis, 42 (60%) patients achieved a spleen
response or symptom reduction by 24 months (Figure 1). Sixty‐three
patients (90%) had a symptom response that occurred in most cases
(73%) within the first 2 months of therapy. Median reductions in
palpable spleen length and TSS were 71.7% and 100%, respectively. A
complete resolution of palpable splenomegaly and of TSS was achieved
in 24 (34.3%) and 42 (60.0%) patients (Figure 2A,B, respectively).
At 3 months, 28 (41.2%) and 50 (72.5%) of 68 and 69 evaluable
patients achieved a spleen or a symptom response, respectively. At
6 months, 35 (54.7%) and 52 (80%) of 64 and 65 evaluable patientsFIGURE 2 A, Best percent change from baseline in palpable spleen
length and, B, in Total Symptom Score by 2 years from RUX start at
any time. Each bar represents data from an individual patient
4 PALANDRI ET AL.achieved a spleen or a symptom response, respectively. Additionally,
25% and 15.6% of patients had 25% to <50% reductions in spleen
lengths at weeks 12 and 24, respectively. After a median ruxolitinib
exposure of 27.3 months (range, 1‐56.2), 27 (39.1%) patients main-
tained their spleen response.
Among baseline features that were tested for correlation with
subsequent spleen or symptoms response at 3 and 6 months, none
was significantly associated with responses.3.3 | Ruxolitinib dose and safety
Ruxolitinib starting dose was ≥10 mg BID in all patients. During the
first 12 weeks of therapy, 32.8% of patients had a decrease in RUX
dose, while only 2 patients were able to increase the dosage. The inci-
dence of RUX dose reductions was slightly higher in patients starting
with 20 mg BID (37.5% versus 19% in patients that started with
<20 mg BID, P = .06). Overall, 80.6% patients could maintain a RUX
dose ≥15 mg BID, and only 7.5% of patients experience reduction to
<10 mg BID. Most notably, starting and average ruxolitinib doses did
not influence the rate of responses at all time points.
Overall, 32 (45.7%) patients experienced RUX‐induced anemia at
any time during RUX therapy, (29%, grade 2; 21.7%, grade 3). At
3 months and 6 months, anemia was observed in 28 (40.6%) and 20
(30.8%) evaluable patients. Fifteen patients required occasional trans-
fusion support. At baseline, all these patients carried a large (>10 cm)
splenomegaly, with a median TSS of 20 (range, 10‐90). At 3 and
6 months, a spleen and symptoms response was achieved by 21.4%
and 50% of the patients, respectively. Three patients acquired an
IWG‐MRT defined transfusion dependency. Thrombocytopenia any
grade occurred in 35 (50.7%) patients (4.4%, grade 2; 2.9%, grade 3).
At 3 months and 6 months, grade ≥2 thrombocytopenia was observed
in 2 and 4 patients; no grade 4 thrombocytopenia was recorded.
Five of 51 (9.8%) patients that were screened for HBV infection
were found to be positive for the HBsAg and for the anti‐HBc antibod-
ies; in two of these patients, a lamivudine prophylaxis was started. No
cases of HBV reactivation were observed. The screening for
Mycobacterium tuberculosis (TBC) was performed with chest X‐ray
and Quantiferon test in 36 patients before ruxolitinib start; in all cases,
no signs of TBC were detected, and no patient received isoniazid
prophylaxis. In 2 patients with a previous study of zoster reactivations,
acyclovir prophylaxis was initiated together with the start of
ruxolitinib. A total of 17 infectious complications ≥grade 2 were
experienced by 12 patients after a median time of 8 months from
ruxolitinib start (range, 2.3‐40.2). Specifically, infections were grade 2
bronchitis (7 cases), grade 2 herpes simplex mucosal infection (3 cases),
grade 3 herpes zoster reactivation (2 cases), grade 2 fever of unknown
origin, urinary tract infection, grade 2 influenza virus infection,
grade 2 Staphylococcus aureus skin infection, and grade 3 bone
TBC infection.3.4 | Treatment discontinuation and overall survival
A total of 12 (17.1%) patients discontinued RUX after a median time of
9.3 months (1‐28.8). Reasons for treatment discontinuation were
acute renal failure (1 case), lung cancer (1), disease progression withoutevolution into acute leukemia (2), infectious complication (boneTBC, 1
case), evolution into acute leukemia (1), and lack or loss of response (6).
Both patients that experienced a disease progression during ruxolitinib
therapy with enlarging splenomegaly and worsening symptoms were
submitted to alloSCT soon after ruxolitinib discontinuation. Overall, 4
patients died because of lung cancer, acute renal failure, complication
after allogeneic transplant, and disease progression without acute
evolution. Death occurred after a mean RUX exposure of 6.6 months
(standard deviation, 4.4); in no case the death was directly attributed
to therapy. Survival at 2 years was 80.1% for a median survival of
56.7 months.4 | DISCUSSION
In real‐world clinical practice, a substantial proportion of patients with
intermediate‐1 risk MF may require ruxolitinib therapy. In the present
report, at 6 months, we observed a rate of spleen responses (54.7%)
that was comparable to that observed at week 24 in the 14 intermedi-
ate‐1 risk patients enrolled in the UK ROBUST trial (57.1%).18 Notably,
similar (63.8%) spleen responses were also observed in the 169
patients enrolled in the JUMP trial demonstrating comparable efficacy
in intermediate‐2/high IPSS risk patients that achieved a spleen length
reduction by ≥50% in 56.9% of the cases. Similarly with the results of
the JUMP study, ruxolitinib starting and average doses did not
correlate with subsequent responses. This may be related to the fact
that almost all patients were titrated to a dose ≥10 mg BID that has
been previously associated with better responses.19
Recently, an ELN‐SIE panel suggested (weak recommendation) the
use of ruxolitinib in intermediate‐1 patients in case of severe (≥15 cm
below LCM) or symptomatic splenomegaly not responsive to hydroxy-
urea/interferon and in case of severe and symptomatic splenomegaly
front‐line.20 Additionally, a TSS >44 was indicated as a good cutoff for
selecting patients with relevant MF‐related symptoms. Here, 45
(65.2%) patients received ruxolitinib because of severe/symptomatic
splenomegaly front‐line or after failure of conventional therapy. In the
remaining cases, ruxolitinib was administered to less symptomatic
patients. The probability to achieve a spleen response at 6 months
was not influenced by baseline disease severity (51.2% in patients
treated according to ELN‐SIE recommendations versus 60.9% in
patients treated with less advanced disease, P = .60). The rate of symp-
tom responses at 6 months was also comparable (78% versus 87%,
P = .51). Additionally, the incidence of drug‐induced anemia at 3months
was comparable among the 2 cohorts (37.8% versus 25%, P = .24). As a
result, the selection of intermediate‐1 patients with substantial clinical
need that has been suggested by the ELN‐SIE panel obviously neither
jeopardize response to therapy nor increase toxicities.
Notably, the rate of responses to ruxolitinib was not influenced by
comorbidities. Consequently, even if the number of patients with
higher CCI was small, comorbidities per se should not be regarded as
contraindication to RUX therapy. Previous studies have demonstrated
that responses to tyrosine kinase inhibitors may be negatively affected
by an increased BMI (>25‐40) at diagnosis.21 In patients with MF
treated with ruxolitinib, no data has been available so far. In this cohort
of selected intermediate‐1 IPSS risk, BMI was above 25 in 50% of
PALANDRI ET AL. 5patients, while only 3 patients presented a low BMI (<18). Notably, nei-
ther a high nor a low BMI influenced the probability to achieve spleen
or symptom response to ruxolitinib.
Hematological toxicity was limited and never caused therapy
discontinuation. Nonetheless, the issue of infections needs attention
and thoughtful consideration, since 17.1% of patients experienced
at least one infectious event. Particularly, uncommon infections
(TBC and HZV reactivation) occurred in 3 patients that did not have
a past medical history positive for this type of infections. Of note,
while hepatitis B serology was performed in most cases (72.6%), the
screening for TBC was assessed only in 51.4% of the cases, with one
patient that was not investigated for TBC baseline that finally devel-
oped a life‐threatening TBC infection. These data reinforce the need
for an accurate infectious evaluation of MF patients before the start
of ruxolitinib treatment.22,23
There is an ongoing debate on the use of ruxolitinib in intermedi-
ate‐1 patients, a population of patients that were excluded
from pivotal clinical trials so far. While early initiation of JAK‐inhibitor
therapy could potentially result in better therapeutic advantage,24,25
the issue of short‐ and long‐term complications need better clarifica-
tion, especially because the duration of treatment in intermediate‐1
patients may be much longer than for high‐risk cases. Beyond the
analysis of patients enrolled in the expanded access study JUMP
(n = 163) and in the Robust trial (n = 14), this is one of the largest
study reporting efficacy and safety of ruxolitinib in this setting. Here,
rates of response in spleen length and symptoms favored efficacy on
both endpoints, with overall good tolerance. Toxicities appeared as
expected, manifesting as anemia (including some transfusion
dependence), thrombocytopenia and notably 16% of patients
experiencing infection. These data support the need for standardized
guidelines that may guide the decision to initiate ruxolitinib therapy in
this risk category, balancing benefit expectations and potential
adverse effects.
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